Kumari Chandrawansa

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology · 2014 · 2.5K citations

Medicine, Oncology, Pharmacotherapy +13

Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane

Linda T. Vahdat, Brian Pruitt, Carol J. Fabian et al. · Journal of Clinical Oncology · 2009 · 245 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer

Diane Reidy‐Lagunes, Efsevia Vakiani, Marwan Fakih et al. · Journal of Clinical Oncology · 2010 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17

RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922 (I4T-IE-JVBE).

H. Wilke, Eric Van Cutsem, Sang Cheul Oh et al. · Journal of Clinical Oncology · 2014 · 92 citations

Medicine, Oncology, Pharmacology +17

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer

Kohei Shitara, Kei Muro, Yasuhiro Shimada et al. · Gastric Cancer · 2015 · 86 citations · Full text

Medicine, Oncology, Pharmacology +9